IP Library Granted Patent US 7,045,677
Granted Patent B2
US 7,045,677 · App. 10/024,597 · Granted May 16, 2006

Fusion proteins incorporating lysozyme

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,045,677
App. No.
10/024,597
Granted
May 16, 2006
Kind
B2
Abstract

A process for the production of a peptide is disclosed, the process comprising expressing in the milk of a transgenic, non-human, placental mammal a fusion protein which comprises the peptide to be expressed linked to a fusion partner protein which is lysozyme. The fusion protein may be separate from the milk and cleaved to yield the target peptide. A transgenic, non-human, placental mammal whose genome incorporates a DNA molecule comprising a coding sequence encoding lysozyme coupled to a peptide is also described.

Claims (13)

1. A transgenic non-human placental mammal whose genome incorporates a DNA molecule comprising a coding sequence operably linked to a control sequence which comprises a promoter from a gene encoding a naturally-derived milk protein, wherein said coding sequence comprises in order a first segment encoding a fusion partner protein which is lysozyme coupled in-frame to a second segment encoding a peptide other than a protein leader sequence and wherein said fusion protein is expressed in the milk of said transgenic animal.

2. A transgenic mammal as claimed in claim 1 , wherein said mammal is selected from the group consisting of a cow, a sheep, a goat, a rabbit, a mouse and a pig.

3. The transgenic animal of claim 1 , wherein said promoter sequence is a β-lactoglobulin promoter.

4. The transgenic animal of claim 1 , wherein said second segment encodes a peptide selected from the group consisting of:

(a) calcitonin;

(b) parathyroid hormone;

(c) glucagon;

(d) glucagon-like-peptide-1;

(e) a magainin;

(f) a histatin;

(g) a protegrin; and

(h) a clavanin.

5. The transgenic animal of claim 1 , wherein said lysozyme is human lysozyme.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 28, 2020
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: PHARMING GROUP N.V.; PHARMING TECHNOLOGIES B.V.; PHARMING INTELLECTUAL PROPERTY B.V.; BROEKMAN INSTITUUT B.V.; PHARMING B.V.; PHARMING AMERICAS B.V.; PHARMING HEALTHCARE, INC.
Reel/Frame 051722/0304 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 16, 2017
From: PHARMING INTELLECTUAL PROPERTY B.V.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042481/0139 →
SECURITY INTEREST Recorded Dec 7, 2016
From: PHARMING INTELLECTUAL PROPERTY B.V.
To: SILICON VALLEY BANK
Reel/Frame 040839/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2005
From: PPL THERAPEUTICS (SCOTLAND) LIMITED
To: PHARMING INTELLECTUAL PROPERTY BV
Reel/Frame 015788/0236 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2002
From: COTTINGHAM, IAN ROBERT; MCCREATH, GRAHAM EDWARD
To: PPL THERAPEUTICS (SCOTLAND) LTD.
Reel/Frame 012895/0245 →